Owlet, Inc. has entered a partnership with Rhapsody to embed data from its FDA‑cleared BabySat infant monitoring device directly into electronic health record (EHR) systems. The collaboration will allow clinicians to view and record real‑time vital‑sign data—pulse, oxygen saturation, activity, and temperature—within their existing EHR workflows, eliminating the need for manual data entry and reducing the risk of errors.
The deal marks a strategic pivot for Owlet from a consumer‑centric business to a deeper clinical presence. By integrating BabySat data into EHRs, the company removes a major barrier for hospitals, enabling seamless remote patient monitoring of high‑risk infants and positioning it to capture reimbursement streams that are currently limited to in‑hospital monitoring. The partnership also signals to investors that Owlet is pursuing higher‑margin enterprise solutions rather than relying solely on consumer subscriptions.
Technically, BabySat is a prescription‑eligible, wireless pulse‑oximeter cleared by the FDA for monitoring infants with pre‑existing medical conditions. Rhapsody’s platform, a global leader in digital health interoperability, provides a standards‑based exchange that translates BabySat’s data into HL7 and FHIR formats, allowing it to flow into any major EHR vendor without custom development. The integration will support real‑time alerts and trend analysis, giving clinicians a fuller view of a newborn’s health status.
From an investor perspective, the partnership expands Owlet’s customer base beyond parents to include hospitals, health systems, and payers. It also enhances the value of Owlet’s data platform, creating a foundation for future enterprise offerings such as Owlet360 and other subscription services that can monetize aggregated infant health data. The move is expected to generate higher‑margin revenue streams and accelerate market penetration in the connected‑health space.
Jonathan Harris, Owlet’s President and CEO, said, “Our partnership with Rhapsody is another step forward in redefining how infant data is integrated and used more effectively within the healthcare system. By connecting BabySat data to the trusted exchange platform, we’re making sharing infant health data simple and empowering families and clinicians to deliver better care.” Sagnik Bhattacharya, CEO of Rhapsody, added, “True interoperability isn’t just about moving data; it’s about making that data meaningful in the moments that matter. By connecting Owlet’s clinically validated monitoring data directly into the EHR, we’re giving clinicians a fuller view of their youngest patients.”
The collaboration aligns with the broader trend of connected health and remote patient monitoring, which has accelerated during the pandemic and is now gaining traction in pediatric care. By providing a seamless data pipeline from home to hospital, Owlet positions itself to capture a growing share of the infant monitoring market and to influence reimbursement policies that reward continuous, data‑driven care.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.